glp 1 and liver disease Revolutionizing MASLD treatment with GLP-1 receptor agonists Glucagon-like peptide (GLP)-1 and GLP-2
Description
[DOI] [PubMed] [Google Scholar] 85.Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al
LlewellynSmith et al., 2011
Results We assessed the same outcomes reported in the key GLP-1 clinical trials: weight loss and HbA1c
95% CI, 0.590.98), as well as a significantly lower incidence rate of HHF (13.0 versus 20.8 per 1,000 person-years
Get clarity with a tailored plan built around you and improving your metabolic health
